Rosetta Genomics (FRA:RQ1) Common Stock : €4.37 Mil (As of Jun. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Rosetta Genomics Common Stock?

Rosetta Genomics's quarterly common stock increased from Sep. 2016 (€2.89 Mil) to Dec. 2016 (€3.26 Mil) and increased from Dec. 2016 (€3.26 Mil) to Jun. 2017 (€4.37 Mil).

Rosetta Genomics's annual common stock increased from Dec. 2014 (€1.48 Mil) to Dec. 2015 (€2.93 Mil) and increased from Dec. 2015 (€2.93 Mil) to Dec. 2016 (€3.26 Mil).

Rosetta Genomics Common Stock Historical Data

The historical data trend for Rosetta Genomics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Common Stock Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Common Stock

Get a 7-Day Free Trial

1.05

1.18

1.48

2.93

3.26

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
Common Stock	Get a 7-Day Free Trial															2.91	2.89	2.89	3.26	4.37

Rosetta Genomics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Rosetta Genomics (FRA:RQ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (FRA:RQ1) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Rosetta Genomics (FRA:RQ1) Headlines

No Headlines